Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study
I Sudano, S Krähenbühl, F Mach… - Therapeutic …, 2024 - journals.sagepub.com
Aims: The HEYMANS study observed patients receiving evolocumab as part of routine
clinical hyperlipidemia management. It was designed to capture data on clinical parameters …
clinical hyperlipidemia management. It was designed to capture data on clinical parameters …
[HTML][HTML] Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study
C Ebenbichler, H Drexel, U Hanusch, H Toplak… - Wiener klinische …, 2024 - Springer
Background This real-world study examined clinical characteristics and dyslipidemia
management among patients initiating evolocumab across 12 European countries. Austrian …
management among patients initiating evolocumab across 12 European countries. Austrian …
[HTML][HTML] Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study
M Lehrke, A Vogt, V Schettler, M Girndt, U Fraass… - Advances in …, 2024 - Springer
Methods Data was collected between 09/2016 and 05/2021 for≤ 6 months before
(retrospectively) and≤ 30 months after evolocumab initiation (prospectively). Patient …
(retrospectively) and≤ 30 months after evolocumab initiation (prospectively). Patient …
Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS …
V Blaha, R Margoczy, I Petrov… - Journal of …, 2023 - journals.sagepub.com
Purpose: We examined clinical characteristics and low-density lipoprotein cholesterol (LDL-
C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern …
C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern …
Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study
KK Ray, E Bruckert, B Van Hout… - European Heart …, 2020 - academic.oup.com
Background 2019 ESC/EAS dyslipidaemia guidelines recommend a 50% lowering in
untreated LDL-C and use of PCSK9 inhibitors (PCSK9i) for patients at very-high …
untreated LDL-C and use of PCSK9 inhibitors (PCSK9i) for patients at very-high …
[HTML][HTML] Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study
Introduction This study characterizes patients receiving evolocumab in clinical practice and
assesses treatment effectiveness, safety and persistence outcomes across five countries …
assesses treatment effectiveness, safety and persistence outcomes across five countries …
[HTML][HTML] Real-world insights into evolocumab use in patients with hyperlipidemia: Canadian analysis from the ZERBINI study
Abstract Background The 2021 Canadian Cardiovascular Society guidelines recommend
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with …
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with …
Effects of evolocumab on cardiovascular events
N Mikhail - Current Cardiology Reviews, 2017 - ingentaconnect.com
Background: Evolocumab is a potent lipid-lowering drug that decreases plasma levels of
lowdensity lipoprotein cholesterol (LDL-C) by 50-60%. FOURIER is a landmark randomized …
lowdensity lipoprotein cholesterol (LDL-C) by 50-60%. FOURIER is a landmark randomized …
30 EVOLOCUMAB USE IN CLINICAL PRACTICE IN ITALY: FINAL DATA OF THE HEYMANS STUDY.
PP Filardi, P Calabrò, G Galasso… - European Heart …, 2022 - academic.oup.com
Background Controlling lipid levels, in particular low-density lipoprotein cholesterol (LDL-C),
is a proven therapeutic approach to reducing cardiovascular (CV) risk. Greater use of …
is a proven therapeutic approach to reducing cardiovascular (CV) risk. Greater use of …
First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study
Objective To present the first registry used to analyse the clinical profile of patients treated
with evolocumab in Spain, including the effectiveness on the lipid profile and safety in the …
with evolocumab in Spain, including the effectiveness on the lipid profile and safety in the …